These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878 [TBL] [Abstract][Full Text] [Related]
6. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group. Sampaio LPB; Manreza MLG; Pessoa A; Gurgel-Giannetti J; Coan AC; Júnior HVL; Embiruçu EK; Henriques-Souza AMM; Kok F Arq Neuropsiquiatr; 2023 Mar; 81(3):284-295. PubMed ID: 37059438 [TBL] [Abstract][Full Text] [Related]
7. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065 [TBL] [Abstract][Full Text] [Related]
8. Management of CLN1 Disease: International Clinical Consensus. Augustine EF; Adams HR; de Los Reyes E; Drago K; Frazier M; Guelbert N; Laine M; Levin T; Mink JW; Nickel M; Peifer D; Schulz A; Simonati A; Topcu M; Turunen JA; Williams R; Wirrell EC; King S Pediatr Neurol; 2021 Jul; 120():38-51. PubMed ID: 34000449 [TBL] [Abstract][Full Text] [Related]
9. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ; Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227 [TBL] [Abstract][Full Text] [Related]
10. Criteria for Critical Care Infants and Children: PICU Admission, Discharge, and Triage Practice Statement and Levels of Care Guidance. Frankel LR; Hsu BS; Yeh TS; Simone S; Agus MSD; Arca MJ; Coss-Bu JA; Fallat ME; Foland J; Gadepalli S; Gayle MO; Harmon LA; Hill V; Joseph CA; Kessel AD; Kissoon N; Moss M; Mysore MR; Papo ME; Rajzer-Wakeham KL; Rice TB; Rosenberg DL; Wakeham MK; Conway EE; Pediatr Crit Care Med; 2019 Sep; 20(9):847-887. PubMed ID: 31483379 [TBL] [Abstract][Full Text] [Related]
11. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188 [TBL] [Abstract][Full Text] [Related]
12. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657 [TBL] [Abstract][Full Text] [Related]
13. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Nickel M; Simonati A; Jacoby D; Lezius S; Kilian D; Van de Graaf B; Pagovich OE; Kosofsky B; Yohay K; Downs M; Slasor P; Ajayi T; Crystal RG; Kohlschütter A; Sondhi D; Schulz A Lancet Child Adolesc Health; 2018 Aug; 2(8):582-590. PubMed ID: 30119717 [TBL] [Abstract][Full Text] [Related]
17. Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. Lourenço CM; Pessoa A; Mendes CC; Rivera-Nieto C; Vergara D; Troncoso M; Gardner E; Mallorens F; Tavera L; Lizcano LA; Atanacio N; Guelbert N; Specola N; Mancilla N; de Souza CFM; Mole SE J Paediatr Child Health; 2021 Apr; 57(4):519-525. PubMed ID: 33377563 [TBL] [Abstract][Full Text] [Related]
18. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ; Hum Reprod; 2018 Sep; 33(9):1602-1618. PubMed ID: 30052961 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic landscape for Batten disease: current treatments and future prospects. Johnson TB; Cain JT; White KA; Ramirez-Montealegre D; Pearce DA; Weimer JM Nat Rev Neurol; 2019 Mar; 15(3):161-178. PubMed ID: 30783219 [TBL] [Abstract][Full Text] [Related]
20. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2). Gissen P; Specchio N; Olaye A; Jain M; Butt T; Ghosh W; Ruban-Fell B; Griffiths A; Camp C; Sisic Z; Schwering C; Wibbeler E; Trivisano M; Lee L; Nickel M; Mortensen A; Schulz A Orphanet J Rare Dis; 2021 May; 16(1):217. PubMed ID: 33980287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]